{"generic":"Tavaborole","drugs":["Kerydin","Tavaborole"],"mono":{"0":{"id":"931000-s-0","title":"Generic Names","mono":"Tavaborole"},"1":{"id":"931000-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931000-s-1-4","title":"Adult Dosing","mono":"<b>Onychomycosis due to dermatophyte, Toenails:<\/b> apply TOPICALLY to affected toenails once daily for 48 weeks; completely cover the toenail, including the undersurface, with each application "},"1":{"id":"931000-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},"3":{"id":"931000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Onychomycosis due to dermatophyte, Toenails<br\/>"}}},"3":{"id":"931000-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931000-s-3-9","title":"Contraindications","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"931000-s-3-10","title":"Precautions","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"931000-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"931000-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Application site erythema (1.6%), Dermatitis, Application site (1.3%), Ingrowing toenail (2.5%), Peeling of skin, Application site (2.7%)<br\/>"},"6":{"id":"931000-s-6","title":"Drug Name Info","sub":{"0":{"id":"931000-s-6-17","title":"US Trade Names","mono":"Kerydin<br\/>"},"2":{"id":"931000-s-6-19","title":"Class","mono":"Antifungal<br\/>"},"3":{"id":"931000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931000-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931000-s-7","title":"Mechanism Of Action","mono":"Tavaborole is an oxaborole antifungal with inhibitory activity against aminoacyl-transfer ribonucleic acid synthetase.<br\/>"},"8":{"id":"931000-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"931000-s-8-26","title":"Excretion","mono":"Renal: primary excretion route; changed drug <br\/>"}}},"9":{"id":"931000-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>topical use only; not for oral, ophthalmic, or intravaginal use<\/li><li>discard unused portion within 3 months of dropper insertion<\/li><li>contents are flammable; avoid heat or flame<\/li><\/ul>"},"10":{"id":"931000-s-10","title":"Monitoring","mono":"improvement in the signs and symptoms of onychomycosis may indicate efficacy<br\/>"},"11":{"id":"931000-s-11","title":"How Supplied","mono":"<b>Kerydin<\/b><br\/>Topical Solution: 5 %<br\/>"},"13":{"id":"931000-s-13","title":"Clinical Teaching","mono":"<ul><li>Avoid use near open flame or excessive heat as product is flammable.<\/li><li>Side effects may include ingrown toenail or application site dermatitis, erythema, or exfoliation.<\/li><li>Tell patient to report persistent irritation at application site (ie, redness, itching, swelling).<\/li><li>Advise patient to apply drug to entire surface of infected toenail as well as under the tip.<\/li><li>Instruct patient to clean and dry nails prior to administration. Allow solution to dry completely once applied.<\/li><li>Counsel patient to avoid contact with skin. Wipe away excess solution from surrounding skin.<\/li><li>Warn patient that drug is not for oral, ophthalmic, or intravaginal use.<\/li><\/ul>"}}}